HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jérôme Mouroux Henri Richelme Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mouroux, J. Articles by Richelme, H. Search for Related Content PubMed PubMed Citation Articles by Mouroux, J. Articles by Richelme, H.

Ann Thorac Surg 1996;61:530-532
© 1996 The Society of Thoracic Surgeons

---

Original Article: General Thoracic

Should Cavitated Bronchopulmonary Cancers Be Considered a Separate Entity?

Departments of Abdominal and Thoracic Surgery and Radiology, Hôpital Pasteur, Nice, France

Accepted for publication October 9, 1995.

Background. This study was designed to identify any clinical, histologic, and prognostic features specific to cavitated bronchopulmonary tumors.

Methods. A total of 353 patients with lung cancer were categorized in two groups on the basis of chest radiograph and computed tomographic findings: 35 patients with cavitated cancers (group I) and 318 patients with noncavitated neoplasms (group II). Cavitation was defined as the presence of air in the tumor at the time of diagnosis and before any treatment or aspiration biopsy. The two groups were compared.

Results. There was no significant difference between the two groups concerning age, smoking history, or the interval to diagnosis, but diabetes (14.3% versus 5%) and fever (28.6% versus 13.5%) were significantly more frequent in group I than in group II. No statistically significant difference was observed between the two groups in tumor site or endoscopic appearance. Cavitated tumors were 1.5 times larger than the noncavitated lesions. Squamous cell carcinoma was significantly more frequent in group I than in group II (82.8% versus 61%). Survival at 1, 3, and 5 years was, respectively, 58.6%, 36.1%, and 22.2% in group I versus 48.2%, 35%, and 23.8% in group II.

Conclusions. Despite several specific features, there appears to be no justification for considering cavitated neoplasms separately from other forms of lung cancer.

This article has been cited by other articles:

				L. B. Gadkowski and J. E. Stout Cavitary Pulmonary Disease Clin. Microbiol. Rev., April 1, 2008; 21(2): 305 - 333. [Abstract] [Full Text] [PDF]

				A. Onn, D. H. Choe, R. S. Herbst, A. M. Correa, R. F. Munden, M. T. Truong, A. A. Vaporciyan, T. Isobe, M. Z. Gilcrease, and E. M. Marom Tumor Cavitation in Stage I Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome Radiology, October 1, 2005; 237(1): 342 - 347. [Abstract] [Full Text] [PDF]